Phaseline

Companies › Ocular Therapeutix

Ocular Therapeutix: clinical trials, targets and expected readouts

1 active drug program in 29 registered trials: 20 Phase 2, 6 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Axitinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) …Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03438708AxitinibPhase 2Clear Cell Renal Cell CarcinomaOncologyMar 2026
NCT05808608AxitinibPhase 1Renal Cell CarcinomaOncologyApr 2026
NCT03595124AxitinibPhase 2Metastatic Renal Cell CarcinomaOncologyNov 2026
NCT02912572AxitinibPhase 2Metastatic Endometrial CancerOncologyNov 2026
NCT05768464AxitinibPhase 2Non-clear Renal Cell CarcinomaOncologyDec 2026
NCT03297606AxitinibPhase 2Lymphoma, Non-HodgkinOncologyDec 2026
NCT03092856AxitinibPhase 2Clear Cell Renal Cell CarcinomaOncologyDec 2026
NCT06495918AxitinibPhase 3Neovascular Age-related Macular DegenerationOphthalmologyJan 2027
NCT03839498AxitinibPhase 2PheochromocytomaOncologyJan 2027
NCT06211114AxitinibPhase 2Collecting Duct CarcinomaOncologyFeb 2027
NCT06889649AxitinibPhase 2Radiation TherapyOncologyFeb 2027
NCT07235085AxitinibPhase 3Non-Proliferative Diabetic RetinopathyOphthalmologyMar 2027
NCT04996823AxitinibPhase 2MelanomaOncologyMar 2027
NCT05817903AxitinibPhase 2Metastatic Renal Cell CarcinomaOncologyApr 2027
NCT03172754AxitinibPhase 1Renal Cell CarcinomaOncologyApr 2027
NCT05384496AxitinibPhase 2Mucosal MelanomaOncologyMay 2027
NCT07172386AxitinibPhase 2Renal Cell Carcinoma (RCC)OncologyJul 2027
NCT06223958AxitinibPhase 3Neovascular Age-Related Macular DegenerationOphthalmologySep 2027
NCT06903312AxitinibPhase 4Renal Cell CancerOncologyOct 2027
NCT07123090AxitinibPhase 2Metastatic Renal Cell CarcinomaOncologyOct 2027
NCT07744932AxitinibPhase 2Oligometastatic Clear Cell Renal Cell CarcinomaOncologyDec 2027
NCT05738694AxitinibPhase 3Renal Cell CarcinomaOncologyDec 2027
NCT05327686AxitinibPhase 2Metastatic Renal Cell CarcinomaOncologyJun 2028
NCT06279403AxitinibPhase 2Immune Checkpoint InhibitorsOncologyJun 2028
NCT04341181AxitinibPhase 2CancerOncologyApr 2029
NCT07469683AxitinibPhase 2Clear Cell Renal Cell CarcinomaOncologyOct 2029
NCT05969496AxitinibPhase 2Renal CancerOncologyNov 2029
NCT07516132AxitinibPhase 3Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyAug 2030
NCT04510597AxitinibPhase 3Metastatic Clear Cell Renal Cell CarcinomaOncologyJul 2033

From the company's SEC filings

Cash of $531m on 2026-09-30; operating cash outflow about $267m a year; runway about 24 months at that burn, to Sep 2028; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FLT1 (1) FLT4 (1) KDR (1)

Companies with the same targets

Hutchmed Merck & Co. (MSD) Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind Betta Pharmaceuticals Criterium Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Immutep S.A.S. ADC Therapeutics Candel Therapeutics Actinium Pharmaceuticals GrandPharma (China)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.